Predictive Outcomes for HER2-enriched Cancer Using Growth and Metastasis Signatures Driven By SPARC.
Güttlein LN, Benedetti LG, Fresno C, Spallanzani RG, Mansilla SF, Rotondaro C, Raffo Iraolagoitia XL, Salvatierra E, Bravo AI, Fernández EA, Gottifredi V, Zwirner NW, Llera AS, Podhajcer OL.
Güttlein LN, et al. Among authors: fresno c.
Mol Cancer Res. 2017 Mar;15(3):304-316. doi: 10.1158/1541-7786.MCR-16-0243-T. Epub 2016 Dec 28.
Mol Cancer Res. 2017.
PMID: 28031408